



CHEPLAPHARM'S THIRD CAPITAL MARKET TRANSACTION FIVE TIMES OVERSUBSCRIBED

London/Greifswald, June 13, 2019 – CHEPLAPHARM Arzneimittel GmbH very successfully closed its third capital markets transaction within just one year. Offering additional 150 million euros Term Loan B (TLB), final demand was close to 800 million euros. Thus, the company has become fully established on the capital market.

“Underpinned by the ratings of all three leading rating agencies – most recently Fitch Ratings assigned a B+ with stable outlook – we once again impressively won the trust of more than 50 investors and have now an outstanding TLB volume of nearly one billion euros“, summarized CFO Jens Rothstein.

Besides benefitting from the supporting market environment, the background for the third capital market appearance was essentially the increase of the credit line, the optimization of interest terms and documentation of the TLB. Thus, CHEPLAPHARM has achieved greater flexibility in financing its ambitious corporate goals.

“The fact that we truly deserve the trust of our investors, our business partners and our employees is also confirmed by having just received the Axia Best Managed Company Award 2019 in May“, CEO Sebastian F. Braun sums up the excellent outcome of the most recent transaction.

The Axia Best Managed Companies (BMC) program is a competition conducted by Deloitte, WirtschaftsWoche and BDI in Germany for successful medium-sized companies with the vision of building a national and global ecosystem of excellently managed mid-sized companies.

About CHEPLAPHARM

CHEPLAPHARM is a pharmaceutical company headquartered in Greifswald, Germany, offering branded and niche products in more than 120 countries worldwide. The family-owned company specializes in selected active substances and indications and focuses on an international Buy And Build Strategy. Working closely with its business partners, CHEPLAPHARM achieves sustainable annual growth rates. CHEPLAPHARM has been one of the fastest-growing pharmaceutical companies in Europe for years with projected annual sales of 500 million euros in 2019.

Please refer to www.cheplapharm.com for additional information.

Contact Investor Relations:

CHEPLAPHARM Arzneimittel GmbH | Jens Remmers | Ziegelhof 24 | 17489 Greifswald | [investor-relations\(at\)cheplapharm.com](mailto:investor-relations(at)cheplapharm.com)